For years, a subset of families with an X-linked movement disorder combining ataxia and spasticity had no genetic answer — their condition simply didn’t map to any known disease gene. A study published February 14, 2026, in Nature Communications by researchers at Ruhr University Bochum and the University of Tübingen has closed that gap, identifying loss-of-function variants in CD99L2, an X-chromosome gene previously known only for a role in the immune system, as a genuine cause of X-linked spastic ataxia.
Finding a needle by pooling a very large haystack
The discovery came out of a gene-burden analysis across 2,811 individuals affected by ataxia, hereditary spastic paraplegia, and dystonia — a scale only reachable by combining unsolved cases from multiple centers and cohorts rather than working from any single clinic’s caseload. That pooled approach is precisely what let the team clear the statistical bar needed to implicate a gene that would otherwise look like background noise in a smaller dataset: rare-disease genetics increasingly depends on this kind of multi-institution, multi-country data pooling, because no single site sees enough patients with an ultra-rare, unsolved presentation to reach significance alone.
From immune protein to neurological disease gene
CD99L2 had no prior connection to the nervous system in the scientific literature — it was known as a cell-surface protein involved in immune function. The Bochum-Tübingen team showed it also acts as an activator for CAPN1, a calcium-dependent protease already linked to a related recessive form of spastic ataxia. Dr. Jonasz Weber’s team in Bochum’s Department of Human Genetics led the functional characterization work, following up genetic findings with cellular experiments; Dr. Tobias Haack at Tübingen supervised the genetic analysis side. “Disease-causing variants lead to disrupted production of the CD99L2 protein in the cell and prevent its interaction with CAPN1,” Weber explained. Without a working CD99L2-CAPN1 interaction, the downstream cellular process the two proteins normally support breaks down, producing the spastic ataxia phenotype.
Why the two disciplines had to work together
The finding only became solid evidence, rather than a statistical curiosity, once genetic association was paired with a demonstrated cellular mechanism. As the research team put it: “Only when both disciplines work closely together can a reliable disease mechanism be derived from a genetic variant.” That combination — large-cohort gene-burden statistics on one side, wet-lab functional validation on the other — is the standard now expected before a candidate gene is accepted as a true disease cause, particularly for X-linked conditions where the pool of informative families is inherently small.
What it means for affected families and clinicians
A confirmed gene means affected families finally have a specific genetic diagnosis rather than an unexplained, unclassified movement disorder — the practical starting point for accurate genetic counseling, family screening, and eventual entry into any future CD99L2-targeted research. For clinical and research-administration audiences, the study is also a clean illustration of how rare-disease gene discovery now runs: as an explicitly collaborative, cross-institutional data-pooling exercise rather than a single-lab effort, with the statistical power to find causal genes coming directly from how many unsolved cases can be combined into one analysis.
Source: Weber, J.J., Haack, T.B., et al., “Loss-of-function variants in the CAPN1 activator CD99L2 cause X-linked spastic ataxia,” Nature Communications, February 14, 2026 (DOI: 10.1038/s41467-026-69337-9); Ruhr University Bochum press release, March 17, 2026.
